These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12217258)

  • 21. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V
    Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 27. [Nephrology update. Kidney protection with antihypertensive drugs: I].
    Stein G; Fünfstück R; Sperschneider H; Ritz E
    Med Klin (Munich); 2002 Sep; 97(9):541-6. PubMed ID: 12371082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
    Parving HH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S19-24. PubMed ID: 1382160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic nephropathy--the family physician's role.
    Roett MA; Liegl S; Jabbarpour Y
    Am Fam Physician; 2012 May; 85(9):883-9. PubMed ID: 22612183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
    Brenner BM; Zagrobelny J
    Kidney Int Suppl; 2003 Feb; (83):S77-85. PubMed ID: 12864880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
    Bakris GL
    Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA; Jindal KK
    Mayo Clin Proc; 1999 Jun; 74(6):559-64. PubMed ID: 10377929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.
    Ruggenenti P; Remuzzi G
    J Hypertens Suppl; 1998 Jan; 16(1):S95-7. PubMed ID: 9534106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.